TABLE 4 Incidence and clinical pattern of drug-induced hepatotoxicity.
From the following article:
Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy
Yohann Loriot, Gabriel Perlemuter, David Malka, Frédérique Penault-Lorca, Valérie Boige, Eric Deutsch, Christophe Massard, Jean Pierre Armand and Jean-Charles Soria
BACK TO ARTICLE| Drug | Incidence of hepatotoxicity (%) | Clinical pattern of hepatotoxicity | Histological features | Physiopathology |
|---|---|---|---|---|
| Erlotinib or gefitinib | 11 (2% grade 2–3) | Cytolytic hepatitis Isolated hyperbilirubinemia | Chronic hepatitis with active necrosis | Direct action (targeting of hepatocytes that overexpress EGFR) UGT1A1 (UD11) inhibition |
| Imatinib | 10 (4% grade 3) | Cytolytic hepatitis | Hepatic necrosis; sometimes mild cholestasis; no granuloma or fatty infiltration | Hypersensitivity Metabolic reaction |
| Gemtuzumab | 2
16 (grade 3–4) 25 (grade 3–4) | Portal hypertension
Cytolitic hepatitis Hyperbilirubinemia | Sinusoidal obstruction syndrome | Exposure to unconjugated calicheamicin in the circulation
Non-specific uptake of the antibody–calicheamicin complex by Kuppfer cells Receptor-mediated uptake of the antibody–calicheamicin complex through CD33 expression |